Trial Profile
Post-marketing Surveillance (PMS) Management of Invasive Mycosis With Posaconazole
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Posaconazole (Primary)
- Indications Invasive bronchopulmonary aspergillosis; Mycoses
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 12 Mar 2015 New trial record